


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

**APPLICATION FOR CLINICAL TRIAL ON TQB6426 “GPC3 ADC” APPROVED
BY FDA**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that TQB6426 “GPC3 antibody-drug conjugate (ADC)”, a national Category 1 new drug self-developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), a subsidiary of the Group, has received an investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA), intended for advanced malignant tumors.

GPC3 is a glycoprotein located on the cell membrane surface, which is barely expressed in normal adult tissues but is highly expressed in hepatocellular carcinoma (HCC) and serves as a biomarker for clinical diagnosis. Furthermore, GPC3 expression is up-regulated in lung squamous cell carcinoma, ovarian cancer, and other malignancies, positioning it as a highly promising target for targeted therapy and immunotherapy. Currently, no GPC3-targeting ADC has been approved for marketing worldwide, and most candidates in this class remain in pre-clinical or early-stage clinical development, highlighting a substantial unmet clinical needs.

Pre-clinical studies have demonstrated that TQB6426 exhibits potent target-binding affinity and selective cytotoxicity against tumor cells. It also demonstrates strong bystander killing activity and in vivo anti-tumor efficacy, both of which are superior to those of similar candidates, demonstrating best-in-class (BIC) potential. As an ADC, TQB6426 utilizes its GPC3-targeting antibody to achieve targeted delivery, thereby precisely delivering the cytotoxic payload to tumor cells. After eliminating GPC3-positive tumor cells, it further kills GPC3-negative tumor cells through a potent bystander effect, effectively overcoming tumor heterogeneity and expanding anti-tumor coverage. Moreover, the specific and high expression of GPC3 in HCC and other solid tumors provides a crucial biological foundation for achieving “precise delivery and targeted tumor killing”.

Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths. In 2022, there were an estimated 870,000 new cases of liver cancer worldwide, with 760,000 deaths. Without effective intervention measures, the number of new cases are expected to increase to 1.52 million and the number of deaths to 1.37 million by 2050, nearly doubling. Among them, China accounts for approximately 42.4% of all global cases. Liver cancer is characterized by insidious onset and rapid progression, approximately 64% of patients are already at an intermediate or advanced stage at initial diagnosis, losing the chance for curative treatment. Even among early-stage patients who undergo curative surgery, the five-year recurrence rate remains as high as 70%. Current targeted therapies, immunotherapies, and combination regimens provide only limited survival benefit for patients with intermediate or advanced disease, highlighting a substantial unmet clinical needs. The development of ADC drugs targeting GPC3, which combines tumor-specific recognition with potent cytotoxic killing, is expected to provide a novel therapeutic paradigm for patients with GPC3-positive HCC. Furthermore, GPC3 expression in other solid malignancies may enable TQB6426 to extend benefit to a broader patient population with solid tumors.

The Group will accelerate the Phase I clinical trial of TQB6426 to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with advanced malignant tumors, with the aim of providing new treatment options for patients with HCC and other solid tumors in the world as early as possible.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 3 September 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.